Artemisinin Resistance Emerges in Ugandan Children with Severe Malaria
Key Insights
A study in Uganda found that some children with severe malaria (search) show partial resistance to artemisinin, a key antimalarial drug.
The resistance is linked to the A675V mutation in the _Plasmodium falciparum (search)_ parasite's _Pfkelch13_ gene, causing slower parasite clearance.
Children with the mutation had significantly longer parasite clearance times, with 37.5% exceeding five hours.
A study conducted in Uganda has revealed evidence of partial resistance to artemisinin, a crucial drug in malaria (search) treatment, among children suffering from severe malaria. The research, published in JAMA, highlights the presence of specific genetic mutations in the Plasmodium falciparum (search) parasite that are associated with slower parasite clearance despite standard therapies. This finding raises concerns about the sustained effectiveness of current malaria treatment protocols.
Genetic Mutation and Parasite Clearance
The study focused on the A675V variation within the Pfkelch13 gene of Plasmodium falciparum (search). Researchers observed that children with this mutation experienced significantly prolonged parasite clearance times compared to those without it. In a cohort of 100 children aged 6 months to 12 years, 11 exhibited signs of partial resistance to artemisinin. Some children with the A675V mutation required treatment for up to 96 hours to clear the infection.
Specifically, 37.5% of children carrying the A675V mutation had parasite clearance times exceeding five hours, a recognized marker for artemisinin resistance. In contrast, only 8.9% of children without the mutation showed similar delays. Although the study identified partial resistance, no direct correlation was found between the resistance mutations and malaria (search) recurrence within 28 days, suggesting that other factors may influence relapse.
Expert Commentary and Implications
According to study co-author Dr. Chandy John, MD, MS, former ASTMH president, the early detection of drug resistance is a worrying sign. The unexpected discovery of patients experiencing recurrence after initial treatment further underscores the complexity of the issue.
An accompanying editorial by malaria (search) expert Dr. Philip Rosenthal emphasizes that this resistance could affect thousands of children in sub-Saharan Africa treated with artesunate. He calls for urgent trials to determine the effect of artemisinin resistance on the efficacy of parenteral artesunate in treating severe malaria, potentially necessitating changes to current treatment strategies.
Treatment Regimen and Study Limitations
The study examined the impact of the Pfkelch13 A675V genetic variation on the effectiveness of the standard treatment regimen, which involves an intravenous injection of artesunate followed by oral artemether/lumefantrine. Limitations of the study include its small sample size and single-site location, which may limit the generalizability of the results.
Addressing the Threat of Drug Resistance
This research is a crucial step in recognizing and understanding the growing threat of drug resistance in malaria (search) treatment across Africa. While many children in the study responded well to treatment, the evidence of partial resistance highlights the need for potential adjustments to current treatment strategies. According to the WHO, Africa accounts for 95% of the 608,000 global malaria deaths annually, with 80% of these deaths occurring in children under five. Addressing this resistance is vital for improving outcomes and saving lives in malaria-endemic regions.